Onco. Treatments Pvt Ltd

05/05/2026

Gamma Probe for Sentinel Node Biopsy.

Made by Globalsonics, Australia.
For more information Please email; [email protected] or call 0333-2242315.

13/04/2026

Pyrexar Hyperthermia another weapon in the fight against cancer.

10/04/2026

https://youtu.be/pptRLAcXujE?si=F6Rg0HfuyQcv5Smv

Rational for adding thermal oncology to your cancer center

10/04/2026

Pyrexar Bas-2000 Hyperthermia Treatment. No side effects, can treat any size of malignant tumor and metastatic condition.

Paul Turner, CTO of Pyrexar Medical, explains the principals of deep regional hyperthermia using radio frequency

31/03/2026

For more information on Pyrexar BSD Series Hyperthermia Systems, please email; [email protected] or call; 0333-2242315

Improve Head and Neck Cancer Treatment with Hyperthermia

Head and Neck cancer is the sixth most common cancer in worldwide according to World Health Organization and the most common cancer in developing countries. With nearly 664,000 new cases annually. Two-thirds of these occurring in developing countries.

Clinical results like the one below reveal that Radiation treatment are more effective when combined with Hyperthermia. Hyperthermia warms the tumor to temperatures in the "fever range" which makes the cancer cells more sensitive to treatment. Normal healthy cells recover while cancer cells die.

Clinical Evidence
Tumor Entity:
Advanced Head and Neck Tumors with Lymph Node Metastasis

Treatment Modality:
In three trials patients with head and neck tumors were randomized to radio(chemo)therapy with or without hyperthermia. Radiotherapy was applied with 2 Gy fractions up to a total dose of 66-70 Gy. Chemotherapy was only applied in the study by Hua et al., to patients with T3-T4 tumors only. Hyperthermia was given once or twice weekly Valdagni, Trento Italy study used BSD-1000.

Clinical Results:
All three studies showed a significant improvement in complete response rate, and higher local tumor control and overall survival rates, or a longer median survival, when radio(chemo)therapy was combined with hyperthermia.

RT alone RT plus Hyperthermia
CR LC OS CR LC OS
Valdagni 41% 5-y 24% 5-y 0% 83% 5-y 69% 5-y 53%
Hua 81% 5-y 79% 5-y 70% 95% 5-y 91% 5-y 78%
Huilgol 42% not reported median 0.40 y 79% not reported median 0.66 y


41 pts, 44 nodes. Radiotherapy 64-70 GY, 5 fractions/week of 2-2.5 Gy
Complete Remission Rate without Hyperthermia: 41 %
Complete Remission Rate with Hyperthermia: 83 %
5yr nodal control RT - 24%; RT+HT - 69%
5yr overall survival RT - 0% RT+HT - 53%
No enhancement of acute or late toxicity
Endorsements:
The combination of Radiotherapy and Hyperthermia is the treatment of choice for Head & Neck Cancer (Level I Evidence) recommended by

DEGRO German Society of Radiation Oncology
DKG Deutsche Krebsgesellschaft, Germany
Dutch Society for Radiation Oncology, The Netherlands
Dutch Cancer Society, The Netherlands
ESHO European Society of Hyperhermic Oncology
Hyperthermia and Chemotherapy:
When hyperthermia is combined with chemotherapy, general treatment guidelines of the ESHO European Society of Hyperthermic Oncology recommend:

Target volume for hyperthermia: The target volume for hyperthermia is the gross tumor volume.
Sequence of treatment modalities: Hyperthermia is given simultaneously with chemotherapy during cytostasis.
Duration of hyperthermia treatment: Superficial hyperthermia total 60 minutes, deep hyperthermia total 90 minutes (including 30 minutes heating-up time) ) at temperatures of 40 to 44 °C in the whole target volume

31/03/2026

For more information on Pyrexar BSD Hyperthermia Systems please email; [email protected] or Call; 0333-2242315.

Improve Esophageal Cancer Treatment Results with Hyperthermia

Esophageal (Oesophageal) cancer is the eighth most common cancer worldwide according to the World Cancer Research Fund International. With nearly 456,000 new cases diagnosed in 2012. About 75% of those cases are diagnosed in Asia.

Level 1 Clinical results like the one below reveal that both Chemotherapy and Radiation treatment are more effective when combined with Hyperthermia. Hyperthermia warms the tumor to temperatures in the "fever range" which makes the cancer cells more sensitive to treatment. Normal healthy cells recover while cancer cells die.

Clinical Evidence
Tumor Entity:
Primary thoracic esophageal cancer stage III and IV

Treatment Modality:
Three randomized studies were performed in esophageal cancer, comparing radio and/or chemotherapy with or without intraluminal hyperthermia. Kitamura et al. compared preoperative radiochemotherapy with or without hyperthermia. Wang et al. compared 60 Gy alone to 40 Gy plus hyperthermia. Sugimachi et al. compared preoperative chemotherapy with or without hyperthermia. Third party hyperthermia devices used.

esophagus ht table

Clinical Results:
Kitamura et al. found a significantly higher pCR in the plus hyperthermia treatment arm: 25% vs 6%.
Wang et al. found a significantly better 3-y overall survival with hyperthermia: 42 vs 24%.

Sugimachi et al. found that the local effects tended to be better in the plus hyperthermia group: improvement of dysphagia 70% vs 40%; radiographic improvement 50% vs 25%, and histopathological evidence of treatment effect 41% vs 19%.
Duration of hyperthermia treatment
Intraluminal hyperthermia total 30 minutes

References:
Kitamura et al. Prospective Randomised Study of Hyperthermia Combined with Chemoradiotherapy for Esophageal Carcinoma. J Surgical Oncology. 1995; 60:55-58.
Wang et al. Intracavitary microwave hyperthermia combined with external irradiation in the treatment of esophageal cancer. Chung Hua Chung Liu Tsa Chih 1996;18:51-54.
Sugimachi et al. Chemotherapy combined with or without hyperthermia for patients with oesophageal carcinoma: a prospective trial. Int J Hyperthermia 1994;10:485-4

31/03/2026

For more information on Pyrexar BSD Series Hyperthermia Systems please email; [email protected] or call; 0333-2242315

Improve Cervical Cancer Treatment Results with Hyperthermia
Cervical cancer is the fourth most common cancer affecting women worldwide according to the World Health Organization. With nearly 528,000 new cases diagnosed every year. It is also the fourth most common cause of cancer death (266,000 deaths in 2012) in women worldwide.

Level 1 Clinical results like the one below reveal that both Chemotherapy and Radiation treatment are more effective when combined with Hyperthermia. Hyperthermia warms the tumor to temperatures in the "fever range" which makes the cancer cells more sensitive to treatment. Normal healthy cells recover while cancer cells die.

Clinical Evidence
Tumor Entity:
A Cochrane review was performed to investigate whether adding hyperthermia to standard radiotherapy or chemoradiation for locally advanced cervical cancer has an impact on local tumor control, survival, and treatment related morbidity. The review included six randomized trials in patients with primary cervical cancer stage IIB, IIIB and IV.

Treatment Modality:
Conventional external beam radiotherapy and brachytherapy, in one trial with chemotherapy as well. Patients were randomized for additional hyperthermia, 3-12 treatments in the period of external radiotherapy.Patients recruitment sites: AMC Amsterdam using a device similar to the earlier designed BSD-1000, Erasmus MC Rotterdam used the BSD-2000 Hyperthermia device.

Clinical Results:
The majority of patients (74%) included in the studies had FIGO stage IIIB cervical carcinoma. Overall, treatment outcome was significantly better for patients receiving the combined treatment. The pooled data analysis yielded a significantly higher complete response rate (RR 0.56; 95% CI 0.39-0.79; p

31/03/2026

For more information on Pyrexar BSD Series Hyperthermia Systems please email; [email protected] or call; 0333 2242315

Randomized trial of hyperthermia and radiation for superficial tumors, Jones et al

By adding twice-weekly hyperthermia treatments to the daily radiation therapy treatments, the success rate for complete response (no cancer) was tripled. Hyperthermia is known to increase blood flow and perfusion, prevent damaged cancer cells from repairing during treatment, and helping the body's immune system identify and destroy cancer cells.

Clinical Results:
One hundred twenty-two patients were enrolled; 109 (89%) were deemed heatable and were randomly assigned. The complete response rate was 66.1% in the HT arm and 42.3% in the no-HT arm. The odds ratio for complete response was 2.7 (95% CI, 1.2 to 5.8; P = .02). Previously irradiated patients had the greatest incremental gain in complete response: 23.5% in the no-HT arm versus 68.2% in the HT arm. No overall survival benefit was seen.